Table 3.

ORs and 95% CIs of lethal prostate cancer, Swedish Watchful Waiting Cohort, 1977 to 2006

Indolent, n (%)Lethal, n (%)ORa (95% CI)ORb (95%CI)ORc (95% CI)
Acute inflammation
 No329 (85.5)202 (87.8)1.00 (Ref)1.00 (Ref)1.00 (Ref)
 Yes56 (14.5)28 (12.2)0.81 (0.50–1.32)0.96 (0.52–1.77)0.80 (0.41–1.57)
Chronic inflammation
 No97 (25.2)67 (29.1)1.00 (Ref)1.00 (Ref)1.00 (Ref)
 Mild198 (51.4)95 (41.3)0.70 (0.47–1.03)0.96 (0.58–1.60)0.94 (0.55–1.62)
 Moderate/severe90 (23.4)68 (29.6)1.10 (0.70–1.70)1.61 (0.89–2.93)1.73 (0.92–3.27)
SA
 No155 (40.3)95 (41.3)1.00 (Ref)1.00 (Ref)1.00 (Ref)
 Yes230 (59.7)135 (58.7)0.96 (0.69–1.34)1.07 (0.71–1.63)1.20 (0.76–1.87)
PAH
 No304 (79.0)186 (80.9)1.00 (Ref)1.00 (Ref)1.00 (Ref)
 Yes81 (21.0)44 (19.1)0.89 (0.59–1.34)0.82 (0.48–1.39)0.92 (0.53–1.61)
PIN
 No348 (90.4)187 (81.3)1.00 (Ref)1.00 (Ref)1.00 (Ref)
 Yes37 (9.6)43 (18.7)2.16 (1.35–3.47)1.89 (1.04–3.42)1.75 (0.94–3.28)
  • aOR unadjusted;

  • bOR adjusted for age at diagnosis, calendar period of diagnosis (1977–1982, 1983–1988, 1989–1993, and 1994–1998),Gleason categories (4–6, 7:3 + 4, 7:4 + 3, and 8–10), acute inflammation, chronic inflammation (none vs. mild vs. moderate/severe), SA, PAH, and PIN;

  • cOR additionally adjusted for tumor stage (T1a vs. T1b) and tumor percent (missing data for 52 patients).